➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Mallinckrodt
Medtronic
AstraZeneca
Merck

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,322,085

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,322,085
Title:Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
Abstract: The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.
Inventor(s): Tamarkin; Dov (Maccabim, IL), Friedman; Doron (Karmei Yosef, IL), Berman; Tal (Rishon Le Ziyyon, IL), Ziv; Enbal (Gedera, IL), Schuz; David (Gimzu, IL)
Assignee: FOAMIX PHARMACEUTICALS LTD. (Rehovot, IL)
Application Number:16/189,767
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 10,322,085

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Leo Pharma As FINACEA azelaic acid AEROSOL, FOAM;TOPICAL 207071-001 Jul 29, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,322,085

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Israel152486Oct 25, 2002

International Family Members for US Patent 10,322,085

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003279493   Start Trial
Australia 2004261063   Start Trial
Australia 2004266502   Start Trial
Australia 2004313285   Start Trial
Australia 2004321183   Start Trial
Australia 2005204341   Start Trial
Australia 2005204347   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Merck
AstraZeneca
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.